Back

Prognostic outcome of ACS in HTX patients after PCI

31 August 2024 (07:55 - 08:50)
Organised by: Logo
Congress Presentation Part of: Risk stratification in percutaneous coronary intervention (1) Revascularisation ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Ms Luisa Elbinger

Bad Oeynhausen (Germany)

8 More presentations in this session

Presentation thumbnail
A new hydration strategy can reduce contrast-induced acute kidney injury after PCI in patients with chronic heart failure and chronic kidney disease: a two-center randomized controlled trial
Professor K. Chen (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
The use of allopurinol in prophylaxis against contrast-induced nephropathy in patients undergoing percutaneous coronary intervention
Doctor K. Mahmoud (Cairo, EG)
Abstract Slides Video
Presentation thumbnail
Clinical impact of systemic inflammation across the spectrum of different high-sensitivity CRP values in patients undergoing percutaneous coronary intervention
Doctor A. Oliva (New York, US)
Abstract Slides Video
Presentation thumbnail
Gender differences in coronary artery disease patterns
Doctor D. Munhoz (Aalst, BE)
Abstract Slides Video
Presentation thumbnail
Impact of neutrophil-to-lymphocyte ratio on clinical outcomes in patients with or without chronic kidney disease undergoing percutaneous coronary intervention
Doctor A. Oliva (New York, US)
Abstract Slides Video

Access the full session

Session thumbnail
Risk stratification in percutaneous coronary intervention (1)

The Event

Event poster

ESC Congress 2024

31 August 2024 07:55 CET
You may be interested in
thumbnail
Congress Presentation
Reduction of cardiac allograft vasculopathy by PCI: Quantification and correlation with outcome after heart transplantation
thumbnail
Congress Presentation
The role of invasive assessment of coronary physiology in detection of microcirculatory dysfunction in patients after heart transplantation
thumbnail
Congress Presentation
Use of PCSK9 inhibitors for hypercholesterolemia treatment after heart transplant in a multicenter cohort

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources